Pfizer Vietnam, VNVC and Tam Anh on April 15 signed an MoU to partner to enhance healthcare solutions in Viet Nam. — Photo Courtesy of Pfizer Vietnam
Pfizer (Vietnam) Limited Company, Vietnam Vaccine Joint Stock Company (VNVC), and Tam Anh General Hospital Ho Chi Minh Joint Stock Company - Tam Anh Research Institute (TAMRI) have signed a memorandum of understanding (MoU) to partner on enhancing healthcare solutions in Viet Nam.
Darrell Oh, Pfizer Vietnam general director, said this partnership is a testament to the company’s commitment to improving healthcare in Viet Nam.
“By combining our expertise and resources, we are confident that we can make a positive impact on healthcare in Viet Nam and improve the lives of patients," he said.
This partnership will focus on collaborating and sharing experiences in the deployment and utilisation of new technology to enhance the capability of healthcare professionals and improve patient education and awareness; ensuring a sustained supply of new innovative vaccines for Vietnamese people; and supporting medical research initiatives, including new initiatives from Tam Anh, through close collaboration and partnership in the field of medical research or building medical data in order to determine disease burden, or to advance medicine/vaccine development and/or improve health results in Viet Nam.
Vu Thi Thu Ha, supply director of VNVC, said VNVC is the top immunisation system in Viet Nam, with a network of 170 vaccination centres across the country and a team of nearly 10,000 highly skilled doctors and nurses.
It owns a modern cold storage system meeting international standards with four deep total cold storages and more than 170 cold storages located at each vaccination centre that can store 400 million vaccine doses at the same time.
It also aims to become a pioneer in bringing new and high-quality vaccines to Vietnamese people.
“Participating in research and investing in science to work with vaccine manufacturers towards developing new vaccines is a vital mission that leads VNVC to co-operate with large and prestigious corporations such as Pfizer,” she said.
Prof. Nguyen Van Tuan, director of TAMRI and director of the Centre for Health Technology, UTS Australia, Academician of the Australian Academy of Medicine (FAHMS), said: “This partnership opens up opportunities to exchange and learn from Pfizer's global clinical trial programmes.” — VNS